DaVita Inc. provides kidney dialysis services, with a market cap of $9.3 billion. Their stock has underperformed, down 13.7% in 2025. The company reported Q2 results, revenue of $3.4 billion, and adjusted EPS of $2.95, up 47.5%. Analysts expect EPS to grow 12.9% to $10.93 for the year.

The stock’s underperformance can be attributed to a dip in treatment and operating margins. Analysts rate DVA as a “Hold.” Truist Financial analyst David MacDonald maintained a “Hold” rating with a lowered price target of $148, implying a 14.7% upside. The mean price target is $156.57, representing a 21.3% premium.

The SPDR S&P Health Care Services ETF outperformed DVA’s stock, with a 4% decline over the past year and 1.1% gains YTD. DVA’s configuration has remained consistent. The Street-high price target of $186 suggests a potential upside of 44.1% from current levels.

Read more at Yahoo Finance: Do Wall Street Analysts Like DaVita Stock?